Biotech’s survival guide; What tariffs could mean for pharma; Congress pushes for $15B federal biotech investment; and morenews2025-04-12T10:00:48+00:00April 12th, 2025|Endpoints News|
Staff cuts sweep across FDA; Tariff rollout raises questions; The R&D 15 is back; and morenews2025-04-05T10:00:54+00:00April 5th, 2025|Endpoints News|
HHS cuts and more from DC; Lyndra winds down; 23andMe files for bankruptcy; and morenews2025-03-29T10:00:21+00:00March 29th, 2025|Endpoints News|
Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and morenews2025-03-22T10:00:49+00:00March 22nd, 2025|Endpoints News|
Updates on health agency nominees; New data from Pfizer, Beam; MASH startup weighs IPO; and morenews2025-03-15T10:00:55+00:00March 15th, 2025|Endpoints News|
FDA and NIH nominees sail through Senate hearings; Tariffs’ early impact on drug manufacturing; AbbVie’s move into the obesity market; and morenews2025-03-08T11:00:24+00:00March 8th, 2025|Endpoints News|
The top 100 biotech investors; FDA vaccine meeting canceled; Can Bill Anderson save Bayer?; and morenews2025-03-01T11:00:53+00:00March 1st, 2025|Endpoints News|
Bourla praises Trump as RFK Jr. preps vaccine review; Will CRISPR matter?; Atomwise hires new CEO; and morenews2025-02-22T11:00:17+00:00February 22nd, 2025|Endpoints News|
Updates from Washington; A trio of Big Pharma deals; What do recent share buybacks mean for M&A?; and morenews2025-02-15T11:00:13+00:00February 15th, 2025|Endpoints News|
Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and morenews2025-02-08T11:00:30+00:00February 8th, 2025|Endpoints News|
